About this document

ATTRUBY: Treatment for ATTR-CM by Muskan Zombarkar is a document available to read on EtoBox.

ATTRUBY™ (acoramidis) is an oral medication approved by the FDA in November 2024 for the treatment of Transthyretin-Mediated Cardiomyopathy (ATTR-CM) in adults, targeting cardiovascular death and hospitalizations. It is administered at a recommended dose of 712 mg twice daily and has common side effects including diarrhea and upper abdominal pain. The drug has no known contraindications but should be used cautiously in specific populations such as pregnant women and those with concurrent medications.

Author

Muskan Zombarkar

Language

EN